- A physician considers prescribing celecoxib, a selective COX-2 inhibitor, over naproxen, a non-selective COX inhibitor, for a patient with a history of PUD. The theoretical basis for celecoxib's improved gastric safety profile is its relative sparing of which enzyme's activity?
Answer: COX-1, which is constitutively expressed in the gastric mucosa and responsible for synthesizing cytoprotective prostaglandins.
The 'housekeeping' enzyme COX-1 is constitutively expressed in many tissues, including the stomach, where it produces prostaglandins essential for mucosal defense. The inflammatory enzyme COX-2 is typically induced at sites of inflammation. Non-selective NSAIDs like naproxen inhibit both, leading to pain relief (from COX-2 inhibition) but also gastric damage (from COX-1 inhibition). Selective COX-2 inhibitors like celecoxib preferentially block COX-2, reducing inflammation while relatively sparing the protective functions of gastric COX-1. B describes the target of the drug for its therapeutic effect, not its safety profile. C misattributes the reason for GI safety; while COX-1 is in platelets, its sparing in the stomach is key. D describes a complex and largely unproven theory.
- An 80-year-old patient taking high-dose prednisone for an autoimmune condition is started on ibuprofen for joint pain. The patient's risk of GI bleeding is now significantly elevated beyond the risk from ibuprofen alone. What is the pathophysiologic basis for the increased risk conferred by concurrent corticosteroid use?
Answer: Corticosteroids inhibit phospholipase A2, reducing arachidonic acid availability and thereby further impairing prostaglandin synthesis and mucosal healing.
When you encounter questions about drug interactions causing GI bleeding, focus on the underlying mechanisms that protect gastric mucosa and how different drugs disrupt these pathways.
NSAIDs like ibuprofen inhibit cyclooxygenase (COX) enzymes, which convert arachidonic acid into prostaglandins. These prostaglandins are crucial for gastric mucosal protection—they stimulate mucus and bicarbonate secretion, promote mucosal blood flow, and support epithelial repair. When NSAIDs block COX, they reduce protective prostaglandin synthesis, making the stomach vulnerable to acid damage.
Corticosteroids compound this problem through a different mechanism in the same pathway. They inhibit phospholipase A2, the enzyme that liberates arachidonic acid from cell membrane phospholipids. With less arachidonic acid available as substrate, prostaglandin synthesis becomes even more impaired. This creates a "double hit"—NSAIDs block the enzymes that make prostaglandins, while corticosteroids reduce the raw material needed for prostaglandin production. The result is severely compromised mucosal defense and dramatically increased bleeding risk.
Choice A is incorrect because corticosteroids don't directly stimulate acid production through H+/K+ ATPase pumps. Choice C misrepresents corticosteroids as directly acidic topical agents, when their effect is systemic and enzymatic. Choice D describes a pharmacokinetic interaction affecting drug metabolism, but the actual mechanism is pharmacodynamic—both drugs independently impair the same protective pathway.
Remember: Drug interactions often involve multiple agents affecting the same physiologic pathway through different mechanisms. Always trace back to the fundamental protective or regulatory systems being disrupted.
- A patient with a long-standing H. pylori infection localized predominantly to the gastric antrum develops a duodenal ulcer. Which pathophysiological sequence best explains the development of this ulcer?
Answer: Antral inflammation reduces somatostatin release from D-cells, leading to disinhibition of G-cells, hypergastrinemia, and increased parietal cell acid secretion.
In antral-predominant H. pylori infection, the inflammation impairs somatostatin-secreting D-cells. Since somatostatin normally inhibits gastrin-secreting G-cells, its reduction leads to G-cell hyperactivity and hypergastrinemia. Elevated gastrin then stimulates parietal cells (directly and via ECL cells/histamine) to produce excess acid, which flows into the duodenum and causes ulceration. B is incorrect because while VacA is a virulence factor, the primary driver of duodenal ulcers is acid hypersecretion. C is incorrect because urease creates a localized neutral pH for the bacteria's survival; it does not cause systemic changes in acid that would trigger compensatory gastrin release. D describes the mechanism for gastric ulcers and gastric cancer (corpus-predominant atrophic gastritis), not duodenal ulcers.
- A patient undergoes a urea breath test. The patient ingests urea labeled with a non-radioactive isotope (13C). A positive result, indicating the presence of H. pylori, is based on the detection of what substance in the patient's exhaled breath?
Answer: 13CO2, produced from the enzymatic cleavage of labeled urea by bacterial urease.
When you encounter urea breath test questions, focus on the specific biochemical pathway that makes this diagnostic test work. H. pylori bacteria produce the enzyme urease, which is key to their survival in the acidic stomach environment.
Here's what happens: When a patient ingests 13C-labeled urea, any H. pylori present will use their urease enzyme to cleave the urea molecule. This enzymatic reaction breaks urea into two products: ammonia (NH₃) and carbon dioxide (CO₂). Since the original urea contained the 13C isotope, the resulting CO₂ becomes 13CO2. This labeled carbon dioxide is absorbed into the bloodstream, transported to the lungs, and exhaled in the breath where it can be detected. Answer D correctly identifies this endpoint.
Answer A is wrong because bicarbonate isn't the direct product of urease activity—CO₂ is. Answer B incorrectly focuses on ammonia as the detected substance. While ammonia is indeed produced by urease, it's not what's measured in the breath; the ammonia helps neutralize stomach acid locally but doesn't reach the breath in detectable amounts. Answer C misunderstands the entire mechanism—unmetabolized urea wouldn't indicate bacterial presence, and the test doesn't depend on barrier damage.
Remember this pattern: diagnostic breath tests typically measure gaseous end products that can reach the lungs. The urea breath test specifically exploits H. pylori's unique urease production, making 13CO2 detection the definitive marker of infection. - A patient with Zollinger-Ellison syndrome has a gastrin-secreting tumor, leading to severe, refractory peptic ulcer disease. The resulting chronic hypergastrinemia causes ulceration primarily by overwhelming mucosal defenses through maximal stimulation of which two cell types in the gastric corpus?
Answer: Enterochromaffin-like (ECL) cells to release histamine and parietal cells via direct receptor binding.
Gastrin is a powerful stimulant of gastric acid secretion. It acts through two main pathways: 1) It directly binds to CCK2 receptors on parietal cells, stimulating the H+/K+ ATPase pump. 2) It binds to receptors on ECL cells, which are the most important pathway, causing them to release histamine. Histamine then acts as a potent paracrine stimulator of parietal cells via H2 receptors. The combination of these effects leads to massive acid hypersecretion. B is incorrect; the tumor's gastrin release bypasses the normal feedback loops involving G-cells and D-cells. C is incorrect; while gastrin has a minor effect on chief cells, the primary pathology is acid secretion. D is incorrect; ECL cells release histamine, not acetylcholine.
- Which statement best contrasts the primary initiating mechanism of gastroduodenal mucosal injury by NSAIDs versus that by H. pylori?
Answer: NSAIDs primarily cause injury by systemically compromising mucosal defense mechanisms, whereas H. pylori primarily initiates injury through direct inflammation and disruption of the epithelial barrier.
When approaching questions about gastroduodenal injury mechanisms, focus on understanding how different agents attack the delicate balance between mucosal protection and gastric acid exposure through distinct pathways.
NSAIDs work systemically by inhibiting cyclooxygenase enzymes, which blocks prostaglandin E2 synthesis throughout the body. Since prostaglandins are crucial for maintaining the protective mucus barrier, stimulating bicarbonate secretion, and promoting mucosal blood flow, this systemic inhibition compromises the stomach's defense mechanisms against its own acid. Meanwhile, H. pylori initiates injury through a localized inflammatory response. The bacteria directly colonize the gastric mucosa, release inflammatory mediators, and disrupt tight junctions between epithelial cells, creating breaks in the protective barrier that allow acid to penetrate and cause ulceration.
Option A incorrectly reverses the mechanisms - H. pylori doesn't systemically inhibit prostaglandins, and NSAIDs don't primarily target immune cells. Option B mischaracterizes both pathways: NSAIDs don't increase acid production (they impair protection), and while H. pylori does produce ammonia, the primary injury mechanism is inflammatory barrier disruption, not ammonia toxicity. Option D describes autoimmune gastritis (not *H. pylori*-mediated injury) and suggests NSAIDs cause topical burns, which isn't their primary mechanism.
The correct answer is C because it accurately captures the systemic nature of NSAID-induced mucosal defense compromise versus the direct inflammatory and barrier-disrupting effects of H. pylori.
Remember: NSAIDs = systemic defense breakdown; H. pylori = local inflammatory barrier disruption.
- A key component of the gastric mucosal defense system is a rapid, restitutive process where healthy epithelial cells at the edge of a superficial injury migrate to cover the defect. This process is highly energy-dependent and relies on adequate mucosal perfusion. Which of the following insults most directly impairs this specific protective mechanism?
Answer: NSAID-induced reduction in prostaglandin synthesis, as prostaglandins are potent vasodilators that help maintain mucosal blood flow.
When you encounter questions about gastric mucosal defense, focus on the specific mechanism being described. This question highlights epithelial restitution - the rapid migration of healthy cells to cover superficial defects. The key detail is that this process is "highly energy-dependent and relies on adequate mucosal perfusion."
The correct answer is C because prostaglandins serve as crucial vasodilators that maintain mucosal blood flow. When NSAIDs inhibit cyclooxygenase enzymes, they reduce prostaglandin E2 and prostacyclin synthesis, leading to vasoconstriction of mucosal vessels. This compromised perfusion directly impairs the energy-dependent restitution process by reducing oxygen and nutrient delivery to migrating epithelial cells.
Let's examine why the other options miss the mark: A) Vagal stimulation actually enhances mucosal defense by promoting acid regulation and doesn't impair cell migration - the premise about "dysregulated healing" from rapid turnover is incorrect. B) While H. pylori urease does produce ammonia, the primary mechanism of injury isn't preventing basement membrane adherence but rather direct cytotoxic damage and inflammatory responses. D) Pepsin does digest proteins, but in the context of restitution, the limiting factor isn't extracellular matrix degradation but rather the cellular energy and perfusion needed for migration.
Remember this pattern: when a question emphasizes that a protective mechanism is "energy-dependent" and requires "adequate perfusion," look for answer choices that directly affect blood flow. NSAIDs consistently appear on pathophysiology exams as culprits in compromising mucosal perfusion through prostaglandin inhibition.
- The Vacuolating cytotoxin A (VacA), a major virulence factor of H. pylori, contributes to ulcer formation by several mechanisms after it is secreted by the bacterium. Which of the following accurately describes a key pathogenic action of VacA?
Answer: It inserts into epithelial and immune cell membranes, forming anion-selective channels and inducing cellular apoptosis.
When analyzing H. pylori virulence factors, focus on how each toxin's specific mechanism contributes to gastric pathology. VacA (Vacuolating cytotoxin A) is particularly important because it directly damages host cells through membrane disruption.
VacA works by inserting into host cell membranes and forming anion-selective channels, particularly chloride channels. This membrane insertion disrupts cellular ion gradients and leads to cytoplasmic vacuolation (hence the name "vacuolating" toxin). The resulting cellular stress triggers apoptosis in both gastric epithelial cells and immune cells like T lymphocytes. This dual action weakens the gastric mucosa while simultaneously impairing local immune responses, creating conditions favorable for ulcer development.
Option A incorrectly describes VacA as directly activating the proton pump. While H. pylori does influence acid secretion, VacA's primary action is membrane channel formation, not enzyme activation. Option B confuses VacA with H. pylori's urease enzyme, which is a separate virulence factor that neutralizes gastric acid and produces toxic ammonia. Option C describes a mechanism more characteristic of bacterial type III secretion systems that inject effector proteins—VacA functions extracellularly by inserting into membranes rather than being injected to phosphorylate intracellular targets.
Remember that H. pylori uses multiple virulence factors simultaneously: urease for acid neutralization, CagA for cellular signaling disruption, and VacA for direct membrane damage. On pathophysiology exams, questions about bacterial toxins often test whether you can match the specific molecular mechanism to the observed cellular effect.
- The final step in gastric acid secretion involves the H+/K+ ATPase pump on the apical membrane of the parietal cell. The activity of this pump is most potently stimulated by the paracrine binding of histamine to which specific receptor type?
Answer: H2 receptors, which are Gs-protein coupled and increase intracellular cyclic AMP (cAMP).
When you encounter questions about gastric acid secretion, focus on the three key stimulatory pathways and their specific receptor mechanisms. The parietal cell responds to neural (acetylcholine), hormonal (gastrin), and paracrine (histamine) signals, but histamine provides the most potent stimulation.
Histamine acts through H2 receptors, which are Gs-protein coupled receptors. When histamine binds to H2 receptors on parietal cells, it activates adenylyl cyclase, dramatically increasing intracellular cAMP levels. This cAMP then activates protein kinase A, which phosphorylates and activates the H+/K+ ATPase pump, leading to robust acid secretion. This makes B correct.
A is wrong because H1 receptors are found primarily in smooth muscle and endothelial cells for allergic responses, not on parietal cells for acid secretion. While H1 receptors are indeed Gq-coupled, they don't mediate gastric acid production.
C describes a real pathway but answers the wrong question. Muscarinic M3 receptors do stimulate parietal cells via acetylcholine and increase intracellular calcium, but the question specifically asks about histamine binding, not acetylcholine.
D also represents an actual pathway (gastrin binding to CCK2 receptors increases calcium), but again, this isn't histamine-mediated stimulation.
Study tip: Remember "H2 = High acid" - histamine's H2 receptors provide the strongest acid secretion stimulus via cAMP. This is why H2 receptor blockers (like ranitidine) are so effective for reducing stomach acid. The other pathways exist but are less potent than histamine's effect.
- A patient presents with epigastric pain that is relieved by eating but recurs 2-3 hours later. Endoscopy reveals a solitary ulcer in the duodenal bulb. This clinical presentation and finding are most classically associated with which underlying etiology?
Answer: *H. pylori*-induced antral gastritis leading to somatostatin depletion and subsequent hypergastrinemia.
When you encounter a patient with duodenal ulcers and the classic pain pattern of relief with eating followed by recurrence 2-3 hours later, think about the underlying mechanisms that create excessive acid production in the duodenum.
The correct answer is B because this describes the most common pathophysiology of duodenal ulcers. When H. pylori infects the gastric antrum, it causes chronic inflammation that damages the somatostatin-producing D cells. Since somatostatin normally inhibits gastrin release, its depletion leads to unopposed gastrin secretion from G cells. This hypergastrinemia drives excessive acid production, which overwhelms the duodenal bulb's protective mechanisms, creating the classic duodenal ulcer pattern.
Option A is incorrect because while NSAIDs do cause ulcers through prostaglandin depletion, they typically cause gastric ulcers more than duodenal ulcers, and the pain pattern described is more characteristic of duodenal disease. Option C describes H. pylori corpus gastritis, which actually causes *hypo*chlorhydria due to destruction of acid-producing parietal cells - this leads to gastric ulcers and gastric cancer risk, not duodenal ulcers. Option D (Zollinger-Ellison syndrome) can cause duodenal ulcers through massive acid hypersecretion, but it's much rarer than H. pylori antral gastritis and often presents with multiple ulcers, not the single duodenal bulb ulcer described.
Remember: Duodenal ulcers are classically associated with H. pylori antral gastritis and hypergastrinemia, while gastric ulcers are more often linked to NSAIDs or H. pylori corpus gastritis with hypochlorhydria.
- A patient with an asymptomatic H. pylori infection begins taking a non-steroidal anti-inflammatory drug (NSAID). This combination significantly increases the risk of PUD compared to either factor alone. What is the most likely reason for this synergistic effect?
Answer: H. pylori impairs mucosal barrier integrity and repair, while the NSAID concurrently reduces protective prostaglandin synthesis, creating a severely compromised mucosa.
The risk is synergistic because the two agents attack the mucosal defense system from different angles. H. pylori causes direct inflammation, produces cytotoxins, and disrupts the epithelial barrier. NSAIDs systemically inhibit prostaglandin synthesis, which is critical for mucus/bicarbonate secretion, blood flow, and epithelial cell restitution (healing). When a mucosa already weakened by H. pylori is stripped of its prostaglandin-dependent defenses and repair mechanisms by an NSAID, the risk of ulceration from gastric acid is dramatically increased. A is not supported by evidence. C is incorrect as NSAIDs do not cause hypergastrinemia. D is incorrect as only H. pylori (in the case of antral gastritis) causes acid hypersecretion; NSAIDs do not.
- A post-operative patient receives intravenous ketorolac, a potent NSAID, for pain management. Despite the drug never coming into direct contact with the gastric lumen via ingestion, the patient remains at high risk for developing PUD. This is because IV administration of ketorolac:
Answer: results in systemic COX-1 inhibition, reducing the synthesis of prostaglandins essential for maintaining mucosal blood flow and bicarbonate secretion.
When you encounter questions about NSAID-induced gastric complications, focus on the mechanism of action rather than the route of administration. NSAIDs cause peptic ulcer disease through systemic effects, not local irritation.
The correct answer is D because ketorolac works by inhibiting cyclooxygenase (COX) enzymes throughout the body once it enters systemic circulation. COX-1 produces prostaglandins that are crucial for gastric protection—they maintain mucosal blood flow, stimulate bicarbonate secretion to neutralize acid, and promote mucus production. When COX-1 is inhibited systemically, these protective prostaglandins are depleted regardless of how the drug was administered, leaving the gastric mucosa vulnerable to acid-induced damage.
Option A is incorrect because while NSAIDs do affect platelet function through COX-1 inhibition, the primary ulcer mechanism isn't spontaneous hemorrhages evolving into ulcers—it's the loss of mucosal protection leading to acid-induced erosion. Option B misrepresents NSAID metabolism; ketorolac isn't converted to an acidic compound that's secreted into gastric juice. Option C describes a mechanism that doesn't exist—NSAIDs don't trigger vagal reflexes that increase acid secretion; their ulcerogenic effect is due to reduced mucosal defense, not increased acid production.
Remember this key principle: NSAID-induced PUD is primarily about weakened mucosal defense (lost prostaglandin protection) rather than increased gastric acid. This systemic effect occurs regardless of administration route, which is why IV NSAIDs still carry significant GI risk.
- The ability of Helicobacter pylori to colonize the human stomach is critically dependent on its capacity to survive transit through the highly acidic lumen to reach the mucus layer. Which mechanism is most crucial for the bacterium's initial survival during this phase?
Answer: Production of the enzyme urease, which hydrolyzes urea into ammonia, creating a neutral microenvironment around the bacterium.
H. pylori produces large amounts of urease. This enzyme enters the bacterial periplasm and cytoplasm, where it encounters urea diffusing in from the gastric juice. It hydrolyzes urea into ammonia (NH3) and carbon dioxide. The ammonia is protonated to ammonium (NH4+), consuming H+ ions from the environment. This reaction effectively creates a protective, neutralized 'cloud' around the bacterium, allowing it to survive the lethal acidity of the stomach long enough to reach and colonize the protective mucus layer. B is incorrect; H. pylori is non-invasive. C is incorrect; while proton pumps exist, urease is the key adaptation. D is incorrect; VacA is a cytotoxin, not an acid neutralizer.
- A 65-year-old patient develops a gastric ulcer after taking enteric-coated naproxen for osteoarthritis for several months. The enteric coating is designed to prevent dissolution in the stomach. The development of the ulcer in this patient is primarily mediated by which mechanism?
Answer: Systemic inhibition of cyclooxygenase-1 (COX-1), leading to decreased synthesis of protective gastric prostaglandins.
The primary mechanism of NSAID-induced peptic ulcer disease is systemic, not topical. NSAIDs are absorbed into the bloodstream and inhibit COX-1 and COX-2 enzymes throughout the body. In the stomach, inhibition of the constitutively active COX-1 enzyme prevents the synthesis of prostaglandins (PGE2 and PGI2), which are crucial for mucosal defense (stimulating mucus and bicarbonate secretion, maintaining blood flow). The fact that the ulcer occurred despite an enteric coating and would also occur with intravenous NSAIDs highlights the systemic nature of this effect. B is a much less significant mechanism. C is incorrect; NSAIDs do not stimulate gastrin. D is a trap; even if the coating were perfect, the systemic effect would cause the ulcer.
- A patient with suspected peptic ulcer disease is treated with omeprazole, a proton pump inhibitor (PPI). The patient's epigastric pain resolves completely within a few days. This rapid symptom relief confirms the central role of which factor in the symptomatic expression of the disease, regardless of the underlying cause (e.g., H. pylori or NSAID use)?
Answer: Gastric acid, as its presence is the final common pathway for causing the mucosal injury and pain associated with an ulcer.
When you encounter questions about peptic ulcer disease and rapid symptom relief with acid suppression, think about the final common pathway that directly causes pain and mucosal damage in ulcers.
The rapid resolution of symptoms with omeprazole reveals that gastric acid is the key mediator of ulcer-related pain, regardless of whether the underlying cause is H. pylori infection or NSAID use. Omeprazole blocks the hydrogen-potassium ATPase pump (proton pump) in gastric parietal cells, dramatically reducing acid secretion within hours. This immediate acid suppression removes the corrosive environment that directly damages exposed nerve endings and inflamed mucosa, explaining the quick pain relief. Acid is indeed the "final common pathway" - whether H. pylori weakens mucosal defenses or NSAIDs reduce protective prostaglandins, it's ultimately the acid contact with vulnerable tissue that generates symptoms.
Option A is incorrect because PPIs don't significantly stimulate prostaglandin synthesis - they work by acid suppression, not prostaglandin restoration. Option B misrepresents PPI mechanisms; omeprazole has no direct bactericidal effects against H. pylori and requires combination with antibiotics for eradication. Option D is wrong because PPIs lack meaningful anti-inflammatory properties - their benefit comes from acid reduction, not inflammation suppression.
Remember this principle: rapid symptom relief with acid suppression in peptic ulcer disease always points to acid as the immediate cause of pain, even when other factors (H. pylori, NSAIDs) initiated the mucosal damage. The acid-pain connection is direct and reversible.
- Helicobacter pylori infection most commonly colonizes the antrum of the stomach. This anatomical preference is primarily because the antrum:
Answer: lacks acid-producing parietal cells, resulting in a slightly higher local pH compared to the corpus, which is more hospitable for the bacterium.
When analyzing H. pylori colonization patterns, you need to understand how gastric anatomy creates different microenvironments that affect bacterial survival. The stomach isn't uniform—different regions have distinct cellular compositions and pH levels.
H. pylori preferentially colonizes the antrum because this region lacks the acid-producing parietal cells that are abundant in the gastric corpus and fundus. Since parietal cells secrete hydrochloric acid, their absence in the antrum creates a relatively higher pH environment compared to other gastric regions. While the antrum is still acidic, this slightly more hospitable pH allows H. pylori to establish and maintain colonization more easily than in the highly acidic corpus.
Looking at the incorrect options: Option A is wrong because mucus layer thickness doesn't significantly differ between gastric regions, and H. pylori actually thrives within the mucus layer rather than needing to bypass it. Option B incorrectly identifies chief cells as promoters of bacterial adhesion—chief cells secrete pepsinogen and are actually more concentrated in the corpus, not the antrum. Option D is factually incorrect because G-cells aren't exclusive to the antrum, and H. pylori doesn't require gastrin as a nutrient; instead, the bacteria can stimulate gastrin release, contributing to peptic ulcer formation.
Remember that H. pylori pathogenesis questions often test your understanding of gastric regional anatomy. Focus on how parietal cell distribution creates pH gradients throughout the stomach—this concept appears frequently in questions about gastric pathology and bacterial colonization patterns.
- The cytoprotective effects of prostaglandins on the gastroduodenal mucosa are critical for preventing peptic ulcer disease. Which of the following is a direct consequence of reduced prostaglandin E2 (PGE2) levels in the gastric mucosa due to NSAID use?
Answer: Decreased secretion of bicarbonate and mucus from epithelial cells, reducing the pH gradient at the cell surface.
Prostaglandins (especially PGE2) are vital for mucosal defense. They bind to EP3 receptors on surface epithelial cells, stimulating the secretion of both a thick mucus layer and bicarbonate-rich fluid. This creates a pH-neutral microenvironment that protects the cells from luminal acid. Inhibition of PGE2 synthesis by NSAIDs directly impairs this primary defense mechanism. B is incorrect; while PGs are pro-survival, their loss doesn't primarily manifest as parietal cell apoptosis. C is incorrect; PGs actually stimulate somatostatin release, so their absence would decrease it. D is partially correct in that PGs inhibit the proton pump, but their most important role is cytoprotection, not acid regulation; the loss of defense is the key insult.
- A researcher is studying a highly pathogenic strain of H. pylori. This strain possesses a gene that encodes a protein injected directly into gastric epithelial cells via a type IV secretion system, where it disrupts intracellular signaling, alters cell polarity, and promotes a pro-inflammatory state. Which virulence factor is being described?
Answer: Cytotoxin-associated gene A (CagA)
CagA is the protein described. It is a key virulence factor found in more pathogenic strains of H. pylori. It is translocated directly into the host cell's cytoplasm using a bacterial type IV secretion system. Once inside, CagA is phosphorylated and interacts with numerous host cell proteins, disrupting cell signaling, morphology, and adhesion, and contributing significantly to inflammation and cancer risk. VacA (B) is secreted but forms pores in membranes; it is not injected. Urease (C) is an enzyme that neutralizes acid locally. OipA (D) is an outer membrane protein involved in adhesion and inflammation but is not injected into the cell like CagA.
- A critically ill patient in an intensive care unit with sepsis and multi-organ failure develops multiple, shallow erosions in the gastric fundus and body. The primary pathophysiologic driver of this acute gastric mucosal damage (stress-related mucosal disease) is best described as:
Answer: Splanchnic vasoconstriction and mucosal ischemia, which compromises energy-dependent processes like cell maintenance and bicarbonate production.
Stress-related mucosal disease, seen in critically ill patients, is fundamentally an ischemic injury. Systemic hypotension and physiologic stress cause shunting of blood away from the gut (splanchnic vasoconstriction). The resulting mucosal ischemia impairs the ability of epithelial cells to produce protective mucus and bicarbonate, regenerate, and maintain intercellular tight junctions. This compromised defense allows gastric acid to cause diffuse, shallow erosions. B, C, and D describe mechanisms related to other forms of PUD or gastritis but are not the primary drivers of stress ulceration.
- If a genetic mutation were to cause a complete absence of somatostatin-producing D-cells in the gastric antrum while leaving the corpus unaffected, which of the following outcomes would be most likely?
Answer: Chronically elevated gastrin levels and increased susceptibility to duodenal ulcers due to unopposed G-cell stimulation.
When you encounter questions about gastric regulation, focus on the delicate balance between stimulatory and inhibitory signals that control acid secretion. Somatostatin from D-cells serves as a crucial "brake" on gastric acid production.
In the gastric antrum, D-cells release somatostatin that directly inhibits G-cells from secreting gastrin. Without this local inhibition, G-cells would continuously release gastrin into circulation. Elevated gastrin stimulates parietal cells in the corpus to produce excess acid, leading to duodenal ulcers since the duodenum receives this highly acidic chyme. This makes answer D correct.
Answer A is wrong because parietal cells don't compensate by downregulating H2 receptors—they would actually be overstimulated by the elevated gastrin. Answer B incorrectly suggests somatostatin has trophic effects on gastric mucosa; somatostatin is actually inhibitory, not growth-promoting. The absence of an inhibitory signal wouldn't cause atrophy. Answer C confuses the pathway—D-cells don't stimulate ECL cells. Instead, gastrin stimulates ECL cells to release histamine, so with elevated gastrin levels, histamine release would increase, not decrease.
Remember this key principle: somatostatin acts as the primary negative feedback mechanism in gastric physiology. When you see questions about D-cell dysfunction, immediately think about what happens when you remove the "brakes"—uncontrolled stimulation of acid secretion pathways. Focus on understanding the paracrine relationships in the gastric antrum versus the corpus.
